| Literature DB >> 36009958 |
Francesco Cavigioli1, Francesca Viaroli1, Irene Daniele1, Michela Paroli1,2, Luigi Guglielmetti1,2, Elena Esposito1,2, Francesco Cerritelli3, Gianvincenzo Zuccotti1,2, Gianluca Lista1.
Abstract
Current neonatal early-onset sepsis (EOS) guidelines lack consensus. Recent studies suggest three different options for EOS risk assessment among infants born ≥35 wks gestational age (GA), leading to different behaviors in the sepsis workup and antibiotic administration. A broad disparity in clinical practice is found in Neonatal Units, with a large number of non-infected newborns evaluated and treated for EOS. Broad spectrum antibiotics in early life may induce different short- and long-term adverse effects, longer hospitalization, and early mother-child separation. In this single-center prospective study, a total of 3002 neonates born in three periods between 2016 and 2020 were studied, and three different workup algorithms were compared: the first one was based on the categorical risk assessment; the second one was based on a Serial Physical Examination (SPE) strategy for infants with EOS risk factors; the third one associated an informatic tool (Neonatal EOS calculator) with a universal extension of the SPE strategy. The main objective of this study was to reduce the number of neonatal sepsis workups and the rate of antibiotic administration and favor rooming-in and mother-infant bonding without increasing the risk of sepsis and mortality. The combined strategy of universal SPE with the EOS Calculator showed a significant reduction of laboratory tests (from 33% to 6.6%; p < 0.01) and antibiotic treatments (from 8.5% to 1.4%; p < 0.01) in term and near-term newborns. EOS and mortality did not change significantly during the study period.Entities:
Keywords: antibiotics; early onset sepsis; infection; mortality; newborns; serial clinical examination
Year: 2022 PMID: 36009958 PMCID: PMC9405114 DOI: 10.3390/antibiotics11081089
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Characteristics of the populations.
| P1 | P2 | P3 | ||
|---|---|---|---|---|
| N | 999 | 1003 | 1000 | |
| GA, wks (mean) | 39 + 4 | 39 + 4 | 39 + 4 | 0.45 * |
| Mean weight, g (SD) | 3292 (461) | 3320 (463) | 3340 (453) | 0.06 * |
| Rectovaginal swabs performed, n (%) | 705 (76.8%) | 847 (85%) | 835 (84%) | 0.48 § |
| GBS-positive status, n (%) | 114 (16%) | 112 (13%) | 126 (15%) | 0.56 § |
| GBS status unknown, n (%) | 205 (20%) | 154 (15.3%) | 161 (16.1%) | 0.43 § |
| PROM > 18 h, n (%) | 99 (10.7%) | 178 (18%) | 208 (21%) | 0.01 § |
| Maternal fever > 38 °C, n (%) | 30 (3.3%) | 53 (5.2%) | 69 (6.9%) | 0.01 § |
| Mode of delivery-vaginal, n (%) | 761 (76.2%) | 798 (79.5%) | 811 (81.1%) | <0.01 § |
| Meconium-stained amniotic fluid, n (%) | 134 (13.4%) | 155 (15.5%) | 139 (13.9%) | 0.43 § |
Absolute frequencies (percentage) for qualitative data and mean (standard deviation) for quantitative data were used to describe the demographic characteristics of the sample. p-values: * ANOVA; § Chi-square.
Main outcomes.
| P1 | P2 | P3 | ||
|---|---|---|---|---|
| N | 999 | 1003 | 1000 | |
| Sepsis Laboratory test, n (%) | 332 (33%) | 115 (11.4%) | 66 (6.6%) | <0.01 § |
| Antibiotic treatment, n (%) | 85 (8.5%) | 73 (7.3%) | 14 (1.4%) | <0.01 § |
| Culture-proven EOS, n (%) | 1 (0.1%) | 3 (0.3%) | 3 (0.3%) | 0.29 § |
| Days of Hospitalization, mean days (SD) | 3.20 (1.5) | 4.16 (1.44) | 3.03 (1.73) | 0.04 * |
Absolute frequencies (percentage) for qualitative data were used to describe the main results. p-values: § Chi-square; * statistically significant difference from the comparison between P1 and P3 with Tukey posthoc analysis.
Odds ratio among the study populations regarding clinical outcomes.
| P2 vs. P1 | P3 vs. P1 | P3 vs. P2 | |
|---|---|---|---|
| Antibiotic treatment | 0.90 (0.65–1.25) | 0.16 (0.09–0.27) | 0.18 (0.1–0.31) |
| Neonates exam | 0.26 (0.20–0.33) | 0.14 (0.11–0.19) | 0.55 (0.4–0.75) |
Comparing the three study periods yielded odds ratios (ORs) for the dichotomous outcome.
Clinical characteristics and EOS risk factors of newborns with culture-proven sepsis.
| N | Study Period | GA | GBS Status | Other Risk Factors | IAP | Onset of Symptoms | Lab Test Prior to Symptoms | Antibiotics Prior to Symptoms | SPE | EOS Score at Birth | Etiology |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | P1 | 36 + 5 | neg | no | no | 5 h | yes | no | no | n.a. | GBS |
| 2 | P2 | 39 + 2 | neg | no | no | 14 h | no | no | no | n.a. | GBS |
| 3 | P2 | 39 + 6 | neg | PROM | no | 12 h | no | no | yes | n.a. |
|
| 4 | P2 | 40 + 4 | neg | Chorio-amnionitis | 2 doses | No symptoms | yes | yes | yes | n.a. | GBS |
| 5 | P3 | 38 + 4 | unknown | Maternal fever | no | At birth | no | no | yes | 0.62 |
|
| 6 | P3 | 36 + 2 | neg | PROM | 2 doses | 9 h | no | no | yes | 0.41 |
|
| 7 | P3 | 40 + 2 | neg | PROM | no | 48 h | no | no | yes | 0.3 | GBS |